TY - JOUR
T1 - Allergic Rhinitis and its Impact on Asthma (ARIA) Phase 4 (2018)
T2 - Change management in allergic rhinitis and asthma multimorbidity using mobile technology
AU - Mobile Airways Sentinel Network (MASK) Study Group
AU - Bousquet, Jean
AU - Hellings, Peter W.
AU - Agache, Ioana
AU - Amat, Flore
AU - Annesi-Maesano, Isabella
AU - Ansotegui, Ignacio J.
AU - Anto, Josep M.
AU - Bachert, Claus
AU - Bateman, Eric D.
AU - Bedbrook, Anna
AU - Bennoor, Kazi
AU - Bewick, Mickael
AU - Bindslev-Jensen, Carsten
AU - Bosnic-Anticevich, Sinthia
AU - Bosse, Isabelle
AU - Brozek, Jan
AU - Brussino, Luisa
AU - Canonica, Giorgio W.
AU - Cardona, Victoria
AU - Casale, Thomas
AU - Cepeda Sarabia, Alfonso M.
AU - Chavannes, Niels H.
AU - Cecchi, Lorenzo
AU - Correia de Sousa, Jaime
AU - Costa, Elisio
AU - Cruz, Alvaro A.
AU - Czarlewski, Wienczyslawa
AU - De Carlo, Giuseppe
AU - De Feo, Giulia
AU - Demoly, Pascal
AU - Devillier, Philippe
AU - Dykewicz, Mark S.
AU - El-Gamal, Yehia
AU - Eller, Esben E.
AU - Fonseca, Joao A.
AU - Fontaine, Jean François
AU - Fokkens, Wytske J.
AU - Guzmán, Maria Antonieta
AU - Haahtela, Tari
AU - Illario, Maddalena
AU - Ivancevich, Juan Carlos
AU - Just, Jocelyne
AU - Kaidashev, Igor
AU - Khaitov, Musa
AU - Kalayci, Omer
AU - Keil, Thomas
AU - Klimek, Ludger
AU - Kowalski, Marek L.
AU - Kuna, Piotr
AU - Schunemann, Holger J.
N1 - Publisher Copyright:
© 2018 American Academy of Allergy, Asthma & Immunology
PY - 2019/3/1
Y1 - 2019/3/1
N2 - Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.
AB - Allergic Rhinitis and its Impact on Asthma (ARIA) has evolved from a guideline by using the best approach to integrated care pathways using mobile technology in patients with allergic rhinitis (AR) and asthma multimorbidity. The proposed next phase of ARIA is change management, with the aim of providing an active and healthy life to patients with rhinitis and to those with asthma multimorbidity across the lifecycle irrespective of their sex or socioeconomic status to reduce health and social inequities incurred by the disease. ARIA has followed the 8-step model of Kotter to assess and implement the effect of rhinitis on asthma multimorbidity and to propose multimorbid guidelines. A second change management strategy is proposed by ARIA Phase 4 to increase self-medication and shared decision making in rhinitis and asthma multimorbidity. An innovation of ARIA has been the development and validation of information technology evidence-based tools (Mobile Airways Sentinel Network [MASK]) that can inform patient decisions on the basis of a self-care plan proposed by the health care professional.
KW - Allergic Rhinitis and Its Impact on Asthma
KW - Change management
KW - asthma
KW - rhinitis
UR - https://www.scopus.com/pages/publications/85056721791
U2 - 10.1016/j.jaci.2018.08.049
DO - 10.1016/j.jaci.2018.08.049
M3 - Article
C2 - 30273709
AN - SCOPUS:85056721791
SN - 0091-6749
VL - 143
SP - 864
EP - 879
JO - Journal of Allergy and Clinical Immunology
JF - Journal of Allergy and Clinical Immunology
IS - 3
ER -